Noel R. Monks

1.1k citations

33 papers · 776 indexed · h-index 16

Biotechnology top 5%
Environmental Chemistry top 10%
Cancer Research
Oncology
- CAR-T cell therapy research 7
- Cancer-related Molecular Pathways 3
Biochemistry top 10%
- Amino Acid Enzymes and Metabolism 7
Genetics
- Virus-based gene therapy research 4
Molecular Biology
- Cancer therapeutics and mechanisms 4
- Melanoma and MAPK Pathways 3
Pulmonary and Respiratory Medicine
- Sarcoma Diagnosis and Treatment 4
Immunology
- interferon and immune responses 2

Co-authors: Jeffrey A. Moscow Arthur B. Pardee Shuqian Liu Hui Yu Yongsheng Xu D K Biswas David Cherba Adriana Brondani da Rocha
Cited by: Biotechnology Environmental Chemistry Cancer Research
Partner nations: United States United Kingdom Brazil

In The Last Decade

Noel R. Monks

32 papers receiving 753 citations

Peers

Countries citing papers authored by Noel R. Monks

Since Specialization

Citations

This map shows the geographic impact of Noel R. Monks's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Noel R. Monks with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Noel R. Monks more than expected).

Fields of papers citing papers by Noel R. Monks

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Noel R. Monks. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Noel R. Monks. The network helps show where Noel R. Monks may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Noel R. Monks, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Noel R. Monks Line = papers co-authored together Noel R. Monks links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Rational design of chimeric antigen receptor T cells against glypican 3 decouples toxicity from therapeutic efficacy Maria Letizia Giardino Torchia,Ryan Gilbreth,Ashley A. Merlino,Erin Sult,Noel R. Monks,Jon Chesebrough,Ravinder Tammali,Nina Chu,Jessica Tong,John Meekin,Kevin Schifferli,Kapil Vashisht,Karma Dacosta,Lori Clarke,Christina Gesse,Xiao-Tao Yao,Courtney R. Bridges,Gordon Moody	2022	7
2	Discovery and Development of MEDI7247, a Novel Pyrrolobenzodiazepine (PBD)-Based Antibody Drug Conjugate Targeting ASCT2, for Treating Hematological Cancers Nabendu Pore,Kevin Schifferli,Noel R. Monks,Ravinder Tammali,M. Jack Borrok,Elaine M. Hurt,Matt Flynn,Marlon C. Rebelatto,Danielle M. Townsley,Mary Jane Hinrichs,Rakesh Dixit,Steven Coats,Ronald Herbst,David A. Tice	2018	7
3	Abstract LB-295: MEDI7247, a novel pyrrolobenzodiazepine ADC targeting ASCT2 with potent in vivo activity across a spectrum of hematological malignancies Noel R. Monks,Kevin Schifferli,Ravinder Tammali,M. Jack Borrok,Steven Coats,Ronald Herbst,David A. Tice,Nabendu Pore	2018	6
4	Oncolytic VSV Primes Differential Responses to Immuno-oncology Therapy Nicholas M. Durham,Kathy Mulgrew,Kelly McGlinchey,Noel R. Monks,Hong Tai Ji,Ronald Herbst,JoAnn Suzich,Scott A. Hammond,Elizabeth J. Kelly	2017	51
5	Anoikis-resistant subpopulations of human osteosarcoma display significant chemoresistance and are sensitive to targeted epigenetic therapies predicted by expression profiling Jessica Foley,Donald J. Scholten,Noel R. Monks,David Cherba,David J. Monsma,Paula Davidson,Dawna Dylewski,Karl Dykema,Mary E. Winn,Matthew R. Steensma	2015	20
6	Using a rhabdomyosarcoma patient-derived xenograft to examine precision medicine approaches and model acquired resistance David J. Monsma,David Cherba,Patrick J. Richardson,Sean Vance,Sanjeet V. Rangarajan,Dawna Dylewski,Emily Eugster,Stephanie B. Scott,Nicole L. Beuschel,Paula Davidson,Richard A. Axtell,Deanna Mitchell,Eric P. Lester,Joseph Junewick,Craig P. Webb,Noel R. Monks	2014	16
7	Melanoma genotypes and phenotypes get personal José M. Pimiento,Eileen M Larkin,Keiran S.M. Smalley,G. Wiersma,Noel R. Monks,Inna V. Fedorenko,Chelsea A. Peterson,Brian J. Nickoloff	2013	16
8	Molecular-guided therapy predictions reveal drug resistance phenotypes and treatment alternatives in malignant peripheral nerve sheath tumors Jacqueline D. Peacock,David Cherba,Kevin Kampfschulte,M. Smith,Noel R. Monks,Craig P. Webb,Matthew R. Steensma	2013	14
9	Comparative RNA-Seq and Microarray Analysis of Gene Expression Changes in B-Cell Lymphomas of Canis familiaris Marie R. Mooney,Jeffrey P. Bond,Noel R. Monks,Emily Eugster,David Cherba,Pamela J. Berlinski,Steve Kamerling,Keith R. Marotti,Heather Simpson,Tony Rusk,Waibhav Tembe,Christophe Legendre,Hollie Benson,Winnie S. Liang,Craig P. Webb	2013	47
10	Genomic characterization of explant tumorgraft models derived from fresh patient tumor tissue David J. Monsma,Noel R. Monks,David Cherba,Dawna Dylewski,Emily Eugster,Hailey Jahn,Sujata Srikanth,Stephanie B. Scott,Patrick J. Richardson,Robin E. Everts,Aleksandr Ishkin,Yuri Nikolsky,James H. Resau,Robert E. Sigler,Brian J. Nickoloff,Craig P. Webb	2012	55
11	Natural Products Genomics: A novel approach for the discovery of anti-cancer therapeutics Noel R. Monks,Bowen Li,Samir Kumar Gunjan,Dennis T. Rogers,Mukul Kulshrestha,Deane L. Falcone,John M. Littleton	2011	8
12	Sensitivity of breast cancer cell lines to recombinant thiaminase I Shuqian Liu,Noel R. Monks,Jeremiah W. Hanes,Tadhg P. Begley,Hui Yu,Jeffrey A. Moscow	2009	19
13	Abrogation of microcystin cytotoxicity by MAP kinase inhibitors and N-acetyl cysteine is confounded by OATPIB1 uptake activity inhibition Abigail Daily,Noel R. Monks,Markos Leggas,Jeffrey A. Moscow	2009	11
14	Metabolism and transport pathways of the blood stable camptothecin AR-67 (7-t-butyldimethylsilyl-10-hydroxycamptothecin) Marta Milewska,Jamie Horn,Noel R. Monks,Jeffrey A. Moscow,Susanne M. Arnold,Markos Leggas	2009	4
15	Targeting the NF-κB pathway in estrogen receptor negative MDA-MB-231 breast cancer cells using small inhibitory RNAs Noel R. Monks,Arthur B. Pardee	2006	15
16	Blocking anti‐apoptosis as a strategy for cancer chemotherapy: NF‐κB as a target Noel R. Monks,D K Biswas,Arthur B. Pardee	2004	58
17	DNA interstrand cross-linking and TP53 status as determinants of tumour cell sensitivity in vitro to the antibody-directed enzyme prodrug therapy ZD2767 Noel R. Monks,David C. Blakey,S. East,Robert I. Dowell,Joanne A. Calvete,Nicola J. Curtin,Christine E. Arris,David R. Newell	2002	21
18	In vitro Cytotoxicity of Extracts from Brazilian Asteraceae Noel R. Monks,Alexandre de Barros Falcão Ferraz,Sérgio Augusto de Loreto Bordignon,Katia R. Machado,Martha Fogliato Santos Lima,Adriana Brondani da Rocha,Gilberto Schwartsmann	2002	23
19	Cellular glutathione as a determinant of the sensitivity of colorectal tumour cell-lines to ZD2767 antibody-directed enzyme prodrug therapy (ADEPT) Noel R. Monks,J A Calvete,Nicola J. Curtin,D C Blakey,S. East,David R. Newell	2000	3
20	Evaluation of the significance of polyamines and their oxidases in the aetiology of human cervical carcinoma Claudio O. Fernández,R. M. Sharrard,M D Talbot,BD Reed,Noel R. Monks	1995	32

About Noel R. Monks

Noel R. Monks is a scholar working on Biochemistry, Oncology and Cancer Research, having authored 33 papers that have together received 776 indexed citations. Recurring topics across this work include Amino Acid Enzymes and Metabolism (7 papers), CAR-T cell therapy research (7 papers), Virus-based gene therapy research (4 papers), Cancer therapeutics and mechanisms (4 papers), Sarcoma Diagnosis and Treatment (4 papers), Melanoma and MAPK Pathways (3 papers), Cancer-related Molecular Pathways (3 papers) and interferon and immune responses (2 papers). The work is most often cited by research in Biotechnology (101 citations), Environmental Chemistry (93 citations) and Cancer Research (132 citations). Noel R. Monks has collaborated with scholars based in United States, United Kingdom and Brazil. Frequent co-authors include Jeffrey A. Moscow, Arthur B. Pardee, Shuqian Liu, Hui Yu, Yongsheng Xu, D K Biswas, David Cherba, Adriana Brondani da Rocha, Gilberto Schwartsmann and Craig P. Webb.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact